Showing 1716 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol…
-
Press release /Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis'…
-
Press release /Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade…
-
Story /This moving personal story about the challenges of living with a rare disease is written by Rocco Falchetto, a biochemist and director of analytical sciences and imaging at the Novartis Institutes for BioMedical Research (NIBR).
-
Press release /Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc…
-
Press release /Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancerMariana Oncology is a preclinical-stage biotechnology company focused…
-
Press release /
Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises
Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in EuropeClinical data showed that use of Adakveo led to a… -
Press release /Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early…
-
Press release /42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1] PREVENT is…